Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H4N4O3 |
Molecular Weight | 168.1103 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NC2=C(N1)C(=O)NC(=O)N2
InChI
InChIKey=LEHOTFFKMJEONL-UHFFFAOYSA-N
InChI=1S/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(H4,6,7,8,9,10,11,12)
Molecular Formula | C5H4N4O3 |
Molecular Weight | 168.1103 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25422986Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/dict/uric-acid.html | http://www.wikidoc.org/index.php/Uric_acid
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25422986
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/dict/uric-acid.html | http://www.wikidoc.org/index.php/Uric_acid
Uric acid, generated from the metabolism of purines, has proven and emerging roles in human disease. Humans produce large quantities of uric acid. Excess serum accumulation of uric acid can lead to a type of arthritis known as gout. Hyperuricemia may increase risk factors for cardiovascular disease. High serum uric acid was associated with higher risk of type 2 diabetes and other diseases.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Urate oxidase (mammals) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2594778 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Serum cystatin C is a better marker for preeclampsia than serum creatinine or serum urate. | 2001 |
|
Comparison of the efficacy of two anti-uric acid diets in dalmatian dogs. | 2001 |
|
Is skeletal muscle damaged by the oxidative stress following anaerobic exercise? | 2001 |
|
Mouse paracentric inversion In(3)55Rk mutates the urate oxidase gene. | 2001 |
|
Prostaglandin inhibition by intraperitoneal indomethacin has no effect on peritoneal permeability during stable CAPD. | 2001 Apr |
|
The potential role of adenosine in the pathophysiology of the insulin resistance syndrome. | 2001 Apr |
|
Hyperuricemia exacerbates chronic cyclosporine nephropathy. | 2001 Apr 15 |
|
Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. | 2001 Apr 9 |
|
Flow-through chemiluminescence sensor using immobilized oxidases for the selective determination of L-glutamate in a flow-injection system. | 2001 Aug |
|
Plasma concentrations of alpha-tocopherol and urate in patients with different types of cancer. | 2001 Aug |
|
Biochemical profile of idiopathic uric acid nephrolithiasis. | 2001 Aug |
|
Reaction of superoxide and nitric oxide with peroxynitrite. Implications for peroxynitrite-mediated oxidation reactions in vivo. | 2001 Aug 3 |
|
Water-soluble antioxidants in human tears: effect of the collection method. | 2001 Dec |
|
Oxidative stress in lavage fluid of preterm infants at risk of chronic lung disease. | 2001 Dec |
|
Localization and topology of a urate transporter/channel, a galectin, in epithelium-derived cells. | 2001 Dec |
|
Allantoin formation and urate and glutathione exchange in human muscle during submaximal exercise. | 2001 Dec 1 |
|
Inhibition of peroxynitrite-induced dityrosine formation with oxidized and reduced thiols, nitric oxide donors, and purine derivatives. | 2001 Feb |
|
Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. | 2001 Feb |
|
Antioxidants and protein carbonyls in bronchoalveolar lavage fluid of children: normal data. | 2001 Feb |
|
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. | 2001 Feb 1 |
|
Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. | 2001 Jan |
|
Role of exercise and ascorbate on plasma antioxidant capacity in thoroughbred race horses. | 2001 Jan |
|
The characteristics of nucleobase transport and metabolism by the perfused sheep choroid plexus. | 2001 Jan 5 |
|
Hypophosphataemia in the metabolic syndrome. Gender differences in body weight and blood glucose. | 2001 Jun |
|
Partially reversible renal tubular damage in patients with obstructive jaundice. | 2001 Jun |
|
Ascorbate acid concentration in airways lining fluid from infants who develop chronic lung disease of prematurity. | 2001 Mar |
|
Contribution of peroxynitrite to the beneficial effects of preconditioning on ischaemia-induced arrhythmias in rat isolated hearts. | 2001 Mar |
|
Ureteropelvic junction obstruction and coexisting renal calculi in children: role of metabolic abnormalities. | 2001 Mar |
|
Binding of urate and caffeine to haemocyanin analysed by isothermal titration calorimetry. | 2001 Mar |
|
Red wine polyphenols, in the absence of alcohol, reduce lipid peroxidative stress in smoking subjects. | 2001 Mar 15 |
|
Flavonoids and urate antioxidant interplay in plasma oxidative stress. | 2001 May |
|
Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. | 2001 May |
|
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. | 2001 May |
|
Modulators of haemocyanin oxygen affinity in the hypoxia- and sulphide-tolerant Baltic isopod Saduria entomon (L.). | 2001 Nov |
|
Intracellular pH, intrauterine growth and the insulin resistance syndrome. | 2001 Nov |
|
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. | 2001 Nov |
|
Expression of the urate transporter/channel is developmentally regulated in human kidneys. | 2001 Nov |
|
Respiratory and circulatory compensation to hypoxia in crustaceans. | 2001 Nov 15 |
|
Isolation and characterization of the DLAD/Dlad genes, which lie head-to-head with the genes for urate oxidase. | 2001 Nov 16 |
|
Tumor lysis syndrome. | 2001 Oct |
|
Gout: radiographic findings mimicking infection. | 2001 Oct |
|
Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. | 2001 Oct |
|
Ozone causes lipid peroxidation but little antioxidant depletion in exercising and nonexercising hamsters. | 2001 Oct |
|
Temperature-sensitive phenotype of Chinese hamster ovary cells defective in PEX5 gene. | 2001 Oct 26 |
|
Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. | 2001 Sep |
|
Concentrations of nucleotides, nucleosides, purine bases, oxypurines, uric acid, and neuron-specific enolase in the cerebrospinal fluid of children with sepsis. | 2001 Sep |
|
A family-based study of metabolic phenotypes in calcium urolithiasis. | 2001 Sep |
|
Xanthine oxidase-derived reactive oxygen species convert flow-induced arteriolar dilation to constriction in hyperhomocysteinemia: possible role of peroxynitrite. | 2002 Jan |
|
Electrosynthesis of poly-o-diaminobenzene on the Prussian Blue modified electrodes for improvement of hydrogen peroxide transducer characteristics. | 2002 Jan |
|
Superoxide mediates shock wave induction of ERK-dependent osteogenic transcription factor (CBFA1) and mesenchymal cell differentiation toward osteoprogenitors. | 2002 Mar 29 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435251
Mice: twice daily with 10 mg per dose for 7 days
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12743010
Uric acid (5 mg/dL) significantly increased MCP-1 production by rat vascular smooth muscle cells at 3, 6, and 24 hours when compared with that of control media.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:20 GMT 2025
by
admin
on
Mon Mar 31 17:50:20 GMT 2025
|
Record UNII |
268B43MJ25
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1916
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
||
|
DSLD |
3056 (Number of products:1)
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
||
|
CFR |
21 CFR 862.1775
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB08844
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
200-720-7
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
SUB32801
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
100000126333
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
69-93-2
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
DTXSID3042508
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
17775
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
1427088
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
268B43MJ25
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
D014527
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
3975
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
C62652
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
m11330
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
1175
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
268B43MJ25
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
URIC ACID
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
INHIBITOR OF FORMATION->TARGET |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
INHIBITOR OF FORMATION->TARGET |
|
||
|
ENZYME->SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
|
||
|
PARENT -> METABOLITE |
|
||
|
PARENT -> METABOLITE |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|